Lifecore Biomedical, Inc. De (LFCR) Net Income towards Common Stockholders (2010 - 2025)

Lifecore Biomedical's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$2.0 million for Q2 2025.

• In Q2 2025, Net Income towards Common Stockholders rose 71.1% year-over-year to -$2.0 million; the TTM figure through May 2025 stood at -$42.6 million (down 273.19% YoY), while the FY2025 annual figure was -$44.4 million, down 469.26% from the prior year.
• Net Income towards Common Stockholders was -$2.0 million for Q2 2025 at Lifecore Biomedical, up from -$15.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $15.6 million in Q1 2024 to a low of -$51.6 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged -$9.0 million across 5 years, with a median of -$3.9 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders plunged 2376.79% in 2022, then jumped 494.4% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$46.0 million in 2021, then jumped by 92.17% to -$3.6 million in 2022, then surged by 494.4% to $14.2 million in 2023, then tumbled by 161.21% to -$8.7 million in 2024, then soared by 76.48% to -$2.0 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$2.0 million (Q2 2025), -$15.7 million (Q1 2025), and -$8.7 million (Q4 2024), per Business Quant data.